{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-004559","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.058805+00:00","generated_at":"2026-05-28T03:20:26.008862+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axsome announces preliminary FY2024 revenue $385.2M; Auvelity $291.4M","bullets":["Total product revenue Q4 $118.3M, full year $385.2M (unaudited preliminary).","Auvelity net product sales Q4 $92.6M, full year $291.4M.","Sunosi net product revenue Q4 $25.7M, full year $93.8M.","CEO cites positive Phase 3 results for AXS-05 (Alzheimer's agitation) and AXS-12 (narcolepsy); regulatory filings planned in 2025.","Active launch preparations underway for AXS-07 (migraine), if approved."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-004559","json":"https://secwatch.observer/filing/0000950170-25-004559.json","markdown":"https://secwatch.observer/filing/0000950170-25-004559.md","text":"https://secwatch.observer/filing/0000950170-25-004559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025004559/0000950170-25-004559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017025004559/axsm-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:20:26.008862+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}